New pill becomes game changer for pancreatic cancer, doubles survival time

Key points

• A new pill could change the way doctors treat pancreatic cancer, one of the deadliest forms of cancer in the world.
• Researchers have found that the drug, called daraxonrasib, nearly doubled survival time in patients with advanced pancreatic cancer whose disease had continued to progress despite chemotherapy.
• Experts are calling the results a potential "game changer" for a cancer that has long been difficult to treat.
• The findings were presented at the American Society of Clinical Oncology (ASCO) meeting and come from a global clinical trial involving 500 patients across North America, Europe and Asia.
• Patients who received the once-daily pill survived for an average of 13.2 months, compared with 6.6 months for those treated with standard chemotherapy.